IHAM
LYEL icon

Integral Health Asset Management’s Lyell Immunopharma LYEL Stock Holding History

Integral Health Asset Management’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-7,000
Closed -$1.08M – 83
2021
Q4 		$1.08M Hold
7,000
– – 0.3% 64
2021
Q3 		$2.07M Buy
+7,000
New +$2.1M 0.6% 54

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
A
Apoletto Road Town, Tortola, British Virgin Islands $260M AUM 31.4% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Integral Health Asset Management's LYEL Position: Q1 2022 in Review

Integral Health Asset Management sold out of Lyell Immunopharma (LYEL) in Q1 2022, closing a stake of 7,000 shares — an estimated $1.08M sold.

Integral Health Asset Management first reported a position in LYEL in Q3 2021 and held it in 2 quarters. The position peaked at $2.07M in Q3 2021. 79 funds tracked by Wall St. Rank hold LYEL as of Q1 2022.

  • Integral Health Asset Management reported no remaining Lyell Immunopharma position as of Q1 2022 after selling out during the quarter.
  • Integral Health Asset Management sold 7,000 Lyell Immunopharma shares in Q1 2022, an estimated $1.08M.
  • Integral Health Asset Management first reported a position in Lyell Immunopharma in Q3 2021 and held it in 2 quarters.
  • Integral Health Asset Management's Lyell Immunopharma position peaked at $2.07M in Q3 2021.
  • 79 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2022.

Based on Integral Health Asset Management's 13F filing for Q1 2022, filed 12 May 2022.